Medscape

FDA Approves Expanded Age Indication for RSV Vaccine

The vaccine was previously approved in the US to prevent LRTD related to RSV infection in adults 60 years or older and ...

GSK's RSV Vaccine Receives Expanded FDA Approval

GSK said the Food and Drug Administration expanded the approved age indication of its RSV vaccine to adults between the ages of 18 and 49 with increased risk of lower respiratory tract disease.
MPR

RSV Vaccine Arexvy Approved for At-Risk Adults Aged 18 to 49 Years

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the Arexvy vaccine.
Yahoo

FDA investigating whether coronavirus vaccines are linked to deaths

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration (FDA) is investigating whether the COVID-19 vaccines were associated with any deaths across all ...